Atovaquone
Antimalarial — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
Also known as: 566C80, mepron
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Atovaquone is an ofp drug in the Antimalarial class catalogued in DrugCentral. It was first approved by the FDA in 1992. DrugCentral lists 7 molecular targets, including ABCG2, Dihydroorotate dehydrogenase and Dhodh. Recorded indications include Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Falciparum malaria, Plasmodium Falciparum Malaria Prevention and Pneumocystis Carinii Pneumonia Prevention.
- Approval status: ofp (first approved 1992 by the FDA).
- Drug class: Antimalarial; Antiprotozoal.
- Molecular targets: ABCG2, Dihydroorotate dehydrogenase, Dhodh and DHODH (7 listed in DrugCentral).
- Indications: Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Falciparum malaria, Plasmodium Falciparum Malaria Prevention, Pneumocystis Carinii Pneumonia Prevention and Pneumocystosis jiroveci pneumonia.
- ATC code: P01AX06 (Other agents against amoebiasis and other protozoal diseases).
- Molecular formula: C22H19ClO3; molecular weight 366.84 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (5)
- Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention
- Falciparum malaria
- Plasmodium Falciparum Malaria Prevention
- Pneumocystis Carinii Pneumonia Prevention
- Pneumocystosis jiroveci pneumonia
Off-label uses (5)
- Babesiosis
- Toxoplasmosis
- Toxoplasmosis associated with acquired immunodeficiency syndrome
- Toxoplasmosis Prevention
- Vivax malaria
Contraindications (8)
- Acute nephropathy
- Anemia due to enzyme deficiency
- Chronic diarrhea
- Disease of liver
- Hepatic failure
- Hyperglycemia
- Malabsorption States
- Vomiting
Mechanism & targets
| Established pharmacologic class | Antimalarial; Antiprotozoal |
|---|
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| ATP-binding cassette sub-family G member 2 | ABCG2 | unknown | IC50 6.64 |
| Dihydroorotate dehydrogenase | — | unknown | IC50 6.37 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Dhodh | unknown | IC50 6.15 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | DHODH | unknown | IC50 5.03 |
| Dihydroorotate dehydrogenase | dhod | unknown | Ki 4.57 |
| Cytochrome b | MT-CYB | inhibitor | — |
| Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial | — | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1992-11-25 | FDA | — | — | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
P01AX06 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES › Other agents against amoebiasis and other protozoal diseases |
P01BB51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Biguanides |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Nocardiosis | 287.6 |
| Pneumocystis jirovecii pneumonia | 198.1 |
| Pancytopenia | 187.7 |
| Malaria | 174.4 |
| Thrombocytopenia | 173.0 |
| Cytokine release syndrome | 165.7 |
| Pulmonary nocardiosis | 163.6 |
| Neutropenia | 151.3 |
| Thrombotic microangiopathy | 150.9 |
| Hepatic cytolysis | 149.6 |
| Immune reconstitution inflammatory syndrome | 149.3 |
| IVth nerve paralysis | 134.8 |
Chemical structure
| Molecular formula | C22H19ClO3 |
|---|---|
| Molecular weight | 366.84 g/mol |
| CAS number | 95233-18-4 |
| InChIKey | KUCQYCKVKVOKAY-CTYIDZIISA-N |
| PubChem CID | 74989 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Atovaquone used for?
DrugCentral lists the following indications for Atovaquone: Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Falciparum malaria, Plasmodium Falciparum Malaria Prevention, Pneumocystis Carinii Pneumonia Prevention and Pneumocystosis jiroveci pneumonia.
How does Atovaquone work?
Its molecular targets in DrugCentral include ABCG2, Dihydroorotate dehydrogenase, Dhodh and DHODH.
When was Atovaquone first approved?
Atovaquone was first approved by the FDA in 1992.
What drug class does Atovaquone belong to?
Atovaquone is in the Antimalarial class.
What is the chemical formula of Atovaquone?
Atovaquone has the molecular formula C22H19ClO3 and a molecular weight of 366.84 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 258 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1450 — compound record and bioactivity
- PubChem CID 74989 — chemical identifiers
- DrugBank DB01117 — drug record
- FDA UNII Y883P1Z2LT — substance identity
- DailyMed: FDA labels for Atovaquone — current prescribing information (label search)
- UniProt Q9UNQ0 (ABCG2) — target protein
- UniProt Q02127 (DHODH) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.